Gemcitabine treatment of tumor-bearing mice reduced the number of splenic and tumor Gr1+/CD11b+ MDSC without affecting the numbers of CD4+ or CD8+ T cells or NK cells [75]. The gene discussed is ITGAM; the disease is neoplasm.